Literature DB >> 22117504

Optimal scoring of serial change on chest radiography in sarcoidosis.

C J Zappala1, S R Desai, S J Copley, R Spagnolo, D Cramer, D Sen, S M Alam, R M du Bois, D M Hansell, A U Wells.   

Abstract

BACKGROUND: The optimal means of quantifying change on chest radiography in sarcoidosis is uncertain. In current guidelines, the role of serial measurement of carbon-monoxide diffusing capacity (DLco) remains undefined and the prevalence of discordance between serial chest radiographic change and pulmonary function tends is unknown.
OBJECTIVE: To identify and explore key uncertainties in the monitoring of sarcoidosis by serial pulmonary function tests and chest radiography.
DESIGN: 354 patients with sarcoidosis and concurrent tests (chest radiography and PFTs within three months at baseline, two years and/or four years) were studied. Chest radiographs were assessed by two radiologists for changes in stage and disease extent. Radiographic change and pulmonary function trends were quantified and compared.
RESULTS: Change in radiographic extent of lung disease was always more frequent than change in stage (p < 0.0001) and there was poor agreement between change in stage and change in radiographic extent (Kw = 0.21 at two years; Kw = 0.23 at four years). Change in disease extent on chest radiography was linked to PFT trends on analysis of variance (p < 0.0005 for FEV1, FVC, DLco), whereas change in radiographic stage was not. Changes in gas transfer were often isolated or discordant with other serial data. Discordance between pulmonary function data and chest radiographic data was observed in 50% of cases.
CONCLUSIONS: Change in radiographic extent is more applicable to routine monitoring in sarcoidosis than change in radiographic stage. In future guidelines, the role of serial gas transfer estimation and reconciliation of divergent chest radiographic and functional trends might usefully be addressed.

Entities:  

Mesh:

Year:  2011        PMID: 22117504

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  7 in total

Review 1.  Imaging of Sarcoidosis.

Authors:  Mario Silva; Hilario Nunes; Dominique Valeyre; Nicola Sverzellati
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

2.  Chest Computed Tomography-Based Scoring of Thoracic Sarcoidosis: Inter-rater Reliability of CT Abnormalities.

Authors:  D A Van den Heuvel; P A de Jong; P Zanen; H W van Es; J P van Heesewijk; M Spee; J C Grutters
Journal:  Eur Radiol       Date:  2015-04-09       Impact factor: 5.315

Review 3.  Treatment of Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

4.  Relationship between radiologic patterns, pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis.

Authors:  Regina Aleksonienė; Ingrida Zeleckienė; Mindaugas Matačiūnas; Roma Puronaitė; Laimutė Jurgauskienė; Radvilė Malickaitė; Edita Strumilienė; Vygantas Gruslys; Rolandas Zablockis; Edvardas Danila
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

5.  Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray.

Authors:  Yuan Zhang; Shan-Shan Du; Meng-Meng Zhao; Qiu-Hong Li; Ying Zhou; Jia-Cui Song; Tao Chen; Jing-Yun Shi; Bing Jie; Wei Li; Li Shen; Fen Zhang; Yi-Liang Su; Yang Hu; Elyse E Lower; Robert P Baughman; Huiping Li
Journal:  BMC Pulm Med       Date:  2022-04-16       Impact factor: 3.317

6.  Repository corticotropin for Chronic Pulmonary Sarcoidosis.

Authors:  Robert P Baughman; Nadera Sweiss; Ruth Keijsers; Surinder S Birring; Ralph Shipley; Lesley Ann Saketkoo; Elyse E Lower
Journal:  Lung       Date:  2017-03-28       Impact factor: 2.584

7.  Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China.

Authors:  Cheng-Wei Li; Ru-Jia Tao; Dan-Feng Zou; Man-Hui Li; Xin Xu; Wei-Jun Cao
Journal:  BMJ Open       Date:  2018-02-16       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.